Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | MAOB | P27338 | 2/20 | 0.43 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.42 |
| ▸ | HTR2A | P28223 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | HGFAC | Q04756 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6408106 | 1.00 | TSHR (0.48) | TSHRMAPTSMN1; SMN2LMNAGAA | |
| SCHEMBL6410126 | 0.83 | MAOB (0.49) | MAPTSMN1; SMN2LMNAMAOBKMT2A | |
| SCHEMBL6410121 | 0.83 | MAOB (0.49) | MAPTSMN1; SMN2LMNAMAOBKMT2A | |
| SCHEMBL5630433 | 0.78 | MAPT (0.43) | MAPTSMN1; SMN2LMNAKMT2ACYP19A1 | |
| SCHEMBL5630443 | 0.78 | MAPT (0.43) | MAPTSMN1; SMN2LMNAKMT2ACYP19A1 | |
| SCHEMBL4781079 | 0.73 | MEN1 (0.57) | TSHRMAPTSMN1; SMN2LMNAGAA | |
| SCHEMBL4390124 | 0.71 | HTR2A (0.50) | MAPTSMN1; SMN2GAAKMT2APKM | |
| SCHEMBL4390129 | 0.71 | HTR2A (0.50) | MAPTSMN1; SMN2GAAKMT2APKM | |
| SCHEMBL23922815 | 0.70 | HTR2A (0.54) | MAPTSMN1; SMN2LMNAGAAKMT2A | |
| SCHEMBL21097121 | 0.70 | HTR2A (0.54) | MAPTSMN1; SMN2LMNAGAAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050107616-A1 | Alpha-ketoamide derivatives as cathepsin k inhibitors | SMITHKLINE BEECHAM CORPORATION | 2005-05-19 | — | — | US | disclosed |
| EP-1411933-A1 | ALPHA-KETOAMIDE DERIVATIVES AS CATHEPSIN K INHIBITORS | SmithKline Beecham Corporation (US) | 2004-04-28 | — | — | EP | disclosed |
| WO-2003013518-A1 | ALPHA-KETOAMIDE DERIVATIVES AS CATHEPSIN K INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-02-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050107616-A1 | Alpha-ketoamide derivatives as cathepsin k inhibitors | CTSK, CTSE, CTSZ | TSHR 3805/4885MAPT 3643/4885SMN1; SMN2 4636/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.